In vivo imaging of tumors with protease-activated near-infrared fluorescent probes

Nature Biotechnology

Volumn 17, Issue 4, 1999, Pages 375-378

  Weissleder, Ralph ^a   Tung, Ching Hsuan ^a   Mahmood, Umar ^a   Bogdanov Jr , Alexei ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Optical imaging; Proteases; Tumor targeting

Indexed keywords

COPOLYMER; FLUORESCENT DYE; FLUOROCHROME; PROTEINASE;

ANIMAL MODEL; ARTICLE; EARLY DIAGNOSIS; ENZYME ACTIVITY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IMAGING; LYSOSOME; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SIGNAL DETECTION; TUMOR;

EID: 0032951071     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/7933     Document Type: Article

References (55)

1. Devita, V., Hellman, S. & Rosenberg, S. Cancer: Principles and Practice of Oncology (Lippincott, Philadelphia, PA, 1997).
2. Stocchi, L. & Nelson, H. Diagnostic and therapeutic applications of monoclonal antibodies in colorectal cancer. Dis. Colon. Rectum. 41, 232-250 (1998).
3. Kopans, D.B. Updated results of the trials of screening mammography. Surg. Oncol. Clin. N. Am. 6, 233-263 (1997).
4. Baum, R.P. & Brummendorf, T.H. Radioimmunolocalization of primary and metastatic breast cancer. Q. J. Nucl. Med. 42, 33-42 (1998).
5. Teates, C.D. & Parekh, J.S. New radiopharmaceuticals and new applications in medicine. Curr. Probl. Diagn. Radiol. 22, 229-266 (1993).
6. Dessureault, S. et al. Pre-operative assessment of axillary lymph node status in patients with breast adenocarcinoma using intravenous 99mtechnetium mAb-170H.82. Breast Cancer Res. Treat. 45, 29-37 (1997).
7. Pasqualini, R., Koivunen, E. & Ruoslahti, E. Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat. Biotechnol. 15, 542-546 (1997).
8. Neri, D. et al. Targeting by affinity-matured recombinant antibody fragments on an angiogenesis associated fibronectin isoform. Nat Biotechnol. 15, 1271-1275 (1997).
9. Buchsbaum, D.J. Experimental tumor targeting with radiolabeled ligands. Cancer 80, 2371-2377 (1997).
10. Rusckowski, M., Qu, T., Chang, F. & Hnatowich, D.J. Technetium-99m labeled epidermal growth factor-tumor imaging in mice. J. Pept. Res. 50, 393-401 (1997).
11. Goodwin, D.A. & Meares, C.F. Pretargeting: general principles: October 10-12, 1996. Cancer 80, 2675-2680 (1997).
12. Jain, R. Delivery of molecular medicine to solid tumors. Science 271, 1079-1080 (1996).
13. Muldoon, L.L. et al. Comparison of intracerebral inoculation and osmotic blood-brain barrier disruption for delivery of adenovirus, herpesvirus, and iron oxide particles to normal rat brain. Am. J. Pathol. 147, 1840-1851 (1995).
14. Roselli, M. et al. Systemic administration of recombinant interferon alfa in carcinoma patients upregulates the expression of the carcinoma-associated antigens tumor-associated glycoprotein-72 and carcinoembryonic antigen. J. Clin. Oncol. 14, 2031-2042 (1996).
15. Leto, G., Gebbia, N., Rausa, L. & Tumminello, F. Cathepsin D in the malignant progression of neoplastic diseases. Anticancer Res. 12, 235-240 (1992).
16. Keppler, D. et al. Tumor progression and angiogenesis: cathepsin B & Co. Biochem. Cell. Biol. 74, 799-810 (1996).
17. Kim, J., Yu, W., Kovalski, K. & Ossowski, L. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell 94, 353-362 (1998).
18. Callahan, R., Bogdanov, A., Fischman, A., Brady, T. & Weissleder, R. Preclinical evaluation and phase I clinical trial of a 99mTc labeled synthetic polymer used In blood pool imaging. AJR 171, 137-143 (1998).
19. Marecos, E., Weissleder, R. & Bogdanov, A., Jr. Antibody-mediated versus non-targeted delivery In a human small cell lung carcinoma model. Bioconjugate Chemistry 6, 184-191 (1998).
20. Quintart, J., Leroy-Houyet, M.A., Trouet, A. & Baudhuin, P. Endocytosis and chloroquine accumulation during tha cell cycle of hepatoma cells in culture. J. Cell Biol. 82, 644-653 (1979).
21. Liaudet, E., Derocq, D., Rochefort, H. & Garcia, M. Transfected cathepsin D stimulates high density cancer cell growth by inactivating secreted growth inhibitors. Cell Growth Differ. 6, 1045-1052 (1995).
22. Garcia, M. et al. Biological and clinical significance of cathepsin D in breast cancer metastasis. Stem Cells 14, 642-650 (1995).
23. Alfano, R.R. et al. Time-resolved and nonlinear optical imaging for medical applications. Ann. NY. Acad. Sci. 838, 14-28 (1998).
24. Alfano, R., Demos, S. & SK, G. Advances in optical imaging of biomedical media. Ann. NY Acad. Sci. 820, 248-270 (1997).
25. Benaron, D.A., Cheong, W.F. & Stevenson, D.K. Tissue optics. Science 276, 2002-2003 (1997).
26. Hebden, J., Arridge, S. & Delpy, D. Optical imaging in medicine: I. experimental techniques. Phys. Med. Biol. 42, 825-840 (1997).
27. Hebden, J.C. & Delpy, D.T. Diagnostic imaging with light. Br. J. Radiol. 70, S206-S214 (1997).
28. Benaron, D.A., Contag, P.R. & Contag, C.H. Imaging brain structure and function, infection and gene expression in the body using light. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 352, 755-761 (1997).
29. Villringer, A. Functional neuroimaging. Optical approaches. Adv. Exp. Med. Biol. 413, 1-18 (1997).
30. Andersson-Engels, S., Klinteberg, C., Svanberg, K. & Svanberg, S. In vivo fluorescence imaging fortissue diagnostics. Phys. Med. Biol. 42, 815-824 (1997).
31. Manoharan, R. et al. Raman spectroscopy and fluorescence photon migration for breast cancer diagnosis and imaging. Photochem. Photobiol. 67, 15-22 (1998).
32. Wu, J., Perelman, L., Dasari, R. & Feld, M. Fluorescence tomographic imaging in turbid media using early-arriving photons and Laplace transforms. Proc. Natl. Acad. Sci. USA 94, 8783-8788 (1997).
33. Yavelow, J., Finlay, T.H., Kennedy, A.R. & Troll, W. Bowman-Birk soybean protease inhibitor as an anticarcinogen. Cancer Res. 43, 2454s-2459s (1983).
34. Yu, A.E., Hewitt, R.E., Connor, E.W. & Stetler-Stevenson, W.G. Matrix metalloproteinases. Novel targets for directed cancer therapy. Drugs & Aging 11, 229-244 (1997).
35. Wojtowicz-Praga, S.M., Dickson, R.B. & Hawkins, M.J. Matrix metalloproteinase inhibitors. Invest. New Drugs 15, 61-75 (1997).
36. Tamura, Y. et al. Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives. J. Med. Chem. 41, 640-649 (1998).
37. Kennedy, A.R. Cancer prevention by protease inhibitors. Prev. Med. 22, 796-811 (1993).
38. Giavazzi, R. et al. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts. Clinical Cancer Research 4, 985-992 (1998).
39. Denis, L.J. & Verweij, J. Matrix metalloproteinase inhibitors: present achievements and future prospects. Invest. New Drugs 15, 175-185 (1997).
40. Bogdanov, A.A. Jr., Martin, C., Bogdanova, A.V., Brady, T.J. & Weissleder, R. An adduct of cis-diamminedichloroplatinum(II) and poly(ethylene glycol)poly(L-lysine)-succinate: synthesis and cytotoxic properties. Bioconj. Chem. 7, 144-149 (1996).
41. Weissleder, R., Cheng, H., Marecos, E., Kwong, K. & Bogdanov, A. Non-invasive in vivo mapping of tumor vascular and interstitial volume fractions. Eur. J. Cancer 34, 1448-1454 (1998).
42. Mitch, W. & Goldberg, A. Mechanism of muscle wasting. N. Engl. J. Med. 335, 1897-1905 (1996).
43. Tsurugi, K. & Ogata, K. Presence of a thiol protease in regenerating rat-liver nuclei. Partial purification and some properties. Eur. J. Biochem. 109, 9-15 (1980).
44. Hashida, S., Towatari, T., Kominami, E. & Katunuma, N. Inhibitions by E-64 derivatives of rat liver cathepsin B and cathepsin L in vitro and in vivo. J. Biochem. (Tokyo) 88, 1805-1811 (1980).
45. Barrett, A.J., Kembhavi, A.A. & Hanada, K. E-64 [L-trans-epoxysuccinyl-leucyl-amido(4-guanidino)butane] and related epoxides as inhibitors of cysteine proteinases. Acta Biol Med Ger 40, 1513-1517 (1981).
46. Shau, H. & Dawson, J.R. Regulation of human natural killing by lysosomotropic and thiol-reactive agents. Immunology 55, 647-654 (1985).
47. Harper, J.W., Hemmi, K. & Powers, J.C. Reaction of serine proteases with substituted isocoumarins: discovery of 3,4-dichloroisocoumarin, a new general mechanism based serine protease inhibitor. Biochemistry 24, 1831-1841 (1985).
48. Hudig, D., Allison, N.J., Kam, C.M. & Powers, J.C. Selective isocoumarin serine protease inhibitors block RNK-16 lymphocyte granule-mediated cytolysis. Mol. Immunol. 26, 793-798 (1989).
49. Powers, J.C. et al. Mechanism-based isocoumarin inhibitors for serine proteases: use of active site structure and substrate specificity in inhibitor design. J. Cell Biochem. 39, 33-46 (1989).
50. Tearney, G. et al. In vivo endoscopic optical biopsy with optical coherence tomography. Science 276, 2037-2039 (1997).
51. el-Shirbiny, A.M. Prostatic specific antigen. Adv. Clin. Chem. 31, 99-133 (1994).
52. Himelstein, B.P., Canete-Soler, R., Bernhard, E.J., Dilks, D.W. & Muschel, R.J. Metalloproteinases in tumor progression: the contribution of MMP-9. Invasion Metastasis 14, 246-258 (1994).
53. Rha, S.Y. et al. Different expression patterns of MMP-2 and MMP-9 in breast cancer. Oncology Reports 5, 875-879 (1998).
54. Berquin, I.M. & Sloane, B.F. Cathepsin B expression in human tumors. Adv. Exp. Med. Biol. 389, 281-294 (1996).
55. Bogdanov, A., Weissleder, R. & Brady, T. Long-circulating blood pool imaging agents. Advanced Drug Delivery Reviews 16, 335-348 (1995).